Recent studies using the Detroit R&D 14,15-DHET ELISA kit revealed that increased EET levels by CYP2J gene therapy or soluble epoxide hydrolase gene deletion in various diabetic mouse or rat models reduced insulin resistance and protected against diabetic nephropathy. Diabetic db/db mice were used or animals were treated with streptozotocin or high levels of fructose or fat in these studies. Rat proximal tubular cells were used to study diabetic nephropathy following high glucose treatment . Screening for DHET levels using the 14,15-DHET ELISA kit in human plasma samples revealed an earlier onset (<40 years old) of type-2 diabetes mellitus (T2DM) in a Chinese population with CYP2J polymorphism.
Our 14,15-DHET ELISA kit provides a powerful tool for both basic research and clinical applications. This ELISA approach is sensitive and quick for measurement of increased EET or DHET levels in various biological samples obtained from human and animals.
|BioTarget 14,15-EET/DHET ELISA Kit for Diabetes||DH2||$414.00|
|BioTarget™ 14,15-DHET ELISA Kit for Diabetes||DH1||$414.00|